NCT06975644View on ClinicalTrials.gov

Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)

NANot yet recruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

September 1, 2026

Study Completion Date

December 31, 2026

Conditions
Triple-Negative Breast Cancer (TNBC)Neoadjuvant ChemotherapyChemotherapy Effects
Interventions
DRUG

nab-paclitaxel, carboplatin, and bemotuzumab

nab-paclitaxel：260 mg/m2 Q3W；carboplatin：AUC 6；bemotuzumab：1200 mg Q3W

DRUG

epirubicin, cyclophosphamide, and bemotuzumab

epirubicin：90 mg/m2 Q3W；cyclophosphamide：600 mg/m2 Q3W；bemotuzumab：1200 mg Q3W

All Listed Sponsors
lead

Zhejiang Provincial People's Hospital

OTHER